The U.S. Food and Drug Administration has granted accelerated approval to Bayer's HYRNUO (sevabertinib) for the first-line treatment of adult ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE